"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA's open ...
Zacks.com on MSN
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions ...
New York, United States, January 7th, 2026, FinanceWireGlobal investment management leader Aurum Capital has announced the ...
Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for ...
Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal ...
LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...
As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house ...
True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...
ASPIRO is the first multi-patient, multi-center clinical trial of an autologous cell therapy for Parkinson's disease. It is evaluating safety, tolerability, and preliminary efficacy of ANPD001 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback